Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.

Cihoric, Nikola; Savic, Mirjana; Schneider, Sabine; Ackermann, I; Bichsel-Naef, Mirjam; Schmid, Ralph; Lardinois, D; Gugger, M; Bubendorf, Lukas; Zlobec, Inti; Tapia, Coya (2014). Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. British journal of cancer, 110(12), pp. 2914-2922. Nature Publishing Group 10.1038/bjc.2014.229

[img]
Preview
Text
bjc2014229a.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-Share Alike (CC-BY-NC-SA).

Download (579kB) | Preview

Background:Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1-amplified and early-stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-characterised early-stage NSCLC.Methods:FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a UICC stage I-II. The FISH results were correlated with clinico-pathological features and overall survival (OS).Results:The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (P<0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly (P=0.0367) worse 5-year OS in patients with an FGFR1-amplified NSCLC.Conclusions:FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery

UniBE Contributor:

Cihoric, Nikola; Savic, Mirjana; Schneider, Sabine; Bichsel-Naef, Mirjam; Schmid, Ralph; Bubendorf, Lukas; Zlobec, Inti and Tapia, Coya

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0007-0920

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Thomas Michael Marti

Date Deposited:

12 Mar 2015 12:17

Last Modified:

11 Jun 2015 02:30

Publisher DOI:

10.1038/bjc.2014.229

PubMed ID:

24853178

BORIS DOI:

10.7892/boris.53736

URI:

https://boris.unibe.ch/id/eprint/53736

Actions (login required)

Edit item Edit item
Provide Feedback